R&D | May 25, 2026
AstraZeneca to showcase cancer pipeline push at ASCO 2026
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Highlighting KEYTRUDA & expanding cancer pipeline
Pharma giant targets new standards of care
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
